Zylo Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Later Stage VC
- (Upcoming)
- Investors
-
14
Zylo Therapeutics General Information
Description
Developer of a topical delivery system intended to enhance drug delivery capabilities. The company's system uses engineered amorphous silica particles to encapsulate compounds and improve product performance by sustained release of medicine, enabling healthcare professionals to treat patients with lupus, hair loss, joint pain, and even burns.
Contact Information
Website
www.zylotherapeutics.comCorporate Office
- 105A Ben Hamby Drive
- Suite 105A
- Greenville, SC 29615
- United States
Corporate Office
- 105A Ben Hamby Drive
- Suite 105A
- Greenville, SC 29615
- United States
Zylo Therapeutics Timeline
Zylo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Later Stage VC | Upcoming | Generating Revenue | ||||
| 14. Accelerator/Incubator | 03-Oct-2023 | Completed | Generating Revenue | |||
| 13. Grant | 31-May-2023 | Completed | Generating Revenue | |||
| 12. Grant | 16-Sep-2022 | Completed | Generating Revenue | |||
| 11. Grant | 19-Aug-2022 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series B) | 03-Jun-2022 | Completed | Generating Revenue | |||
| 9. Early Stage VC | 17-Nov-2021 | Completed | Generating Revenue | |||
| 8. Grant | 19-Jul-2021 | Completed | Generating Revenue | |||
| 7. Grant | 19-Jul-2021 | $1.7M | $12M | Completed | Generating Revenue | |
| 6. Early Stage VC (Series B) | 15-Jul-2021 | $3M | $12M | Completed | Generating Revenue |
Zylo Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Zylo Therapeutics Comparisons
Industry
Financing
Details
Zylo Therapeutics Competitors (4)
One of Zylo Therapeutics’s 4 competitors is Dermata, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dermata | Formerly VC-backed | San Diego, CA | ||||
| SaNOtize | Venture Capital-Backed | Vancouver, Canada | ||||
| Sol-Gel Technologies | Formerly PE-Backed | Ness Ziona, Israel | ||||
| NVN Liquidation | Formerly VC-backed | Durham, NC |
Zylo Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zylo Therapeutics Patents
Zylo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3164746-A1 | Sulfur functionalized monoliths and particles derived from the same as nitric oxide carriers for pharmaceutical and cosmetic applications | Pending | 19-Jun-2019 | ||
| EP-4048289-A1 | Sulfur functionalized monoliths and particles derived from the same as nitric oxide carriers for pharmaceutical and cosmetic applications | Inactive | 19-Jun-2019 | ||
| AU-2020296106-A1 | Sulfur functionalized monoliths and particles derived from the same as nitric oxide carriers for pharmaceutical and cosmetic applications | Pending | 19-Jun-2019 | ||
| EP-4048289-A4 | Sulfur functionalized monoliths and particles derived from the same as nitric oxide carriers for pharmaceutical and cosmetic applications | Inactive | 19-Jun-2019 | ||
| US-20230355662-A1 | Sulfur functionalized monoliths and particles derived from the same as nitric oxide carriers for pharmaceutical and cosmetic applications | Pending | 19-Jun-2019 | A61K33/00 |
Zylo Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zylo Therapeutics Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Endless Frontier Labs | Accelerator/Incubator | |||
| National Institutes of Arthritis and Musculoskeletal Diseases | Other | |||
| National Institute Of Allergy and Infectious Diseases | Government | |||
| Arcview Ventures | Corporate Venture Capital | Minority | ||
| NIH Seed | Not-For-Profit Venture Capital |
Zylo Therapeutics Investments (1)
Zylo Therapeutics’s most recent deal was a Joint Venture with Joint Venture (Silo Pharma / Zylo Therapeutics). The deal was made on 11-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Joint Venture (Silo Pharma / Zylo Therapeutics) | 11-Aug-2021 | Joint Venture | Drug Discovery |
Zylo Therapeutics FAQs
-
When was Zylo Therapeutics founded?
Zylo Therapeutics was founded in 2017.
-
Where is Zylo Therapeutics headquartered?
Zylo Therapeutics is headquartered in Greenville, SC.
-
What is the size of Zylo Therapeutics?
Zylo Therapeutics has 8 total employees.
-
What industry is Zylo Therapeutics in?
Zylo Therapeutics’s primary industry is Drug Delivery.
-
Is Zylo Therapeutics a private or public company?
Zylo Therapeutics is a Private company.
-
What is Zylo Therapeutics’s current revenue?
The current revenue for Zylo Therapeutics is .
-
How much funding has Zylo Therapeutics raised over time?
Zylo Therapeutics has raised $17.5M.
-
Who are Zylo Therapeutics’s investors?
Endless Frontier Labs, National Institutes of Arthritis and Musculoskeletal Diseases, National Institute Of Allergy and Infectious Diseases, Arcview Ventures, and NIH Seed are 5 of 14 investors who have invested in Zylo Therapeutics.
-
Who are Zylo Therapeutics’s competitors?
Dermata, SaNOtize, Sol-Gel Technologies, and NVN Liquidation are competitors of Zylo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
